Source - LSE Regulatory
RNS Number : 7756V
Dechra Pharmaceuticals PLC
16 April 2021
 

 

 

 

16 April 2021

 

 

Dechra Pharmaceuticals PLC

Notification of Transactions by Persons Discharging Managerial Responsibilities

 

 

On 16 April 2021, Dechra Pharmaceuticals PLC was notified by a Director of the Company and Person Discharging Managerial Responsibilities that he had completed the sale of part of his beneficial interest in Dechra.

 

Tony Griffin, Executive Director, has sold 25,000 ordinary shares in the Company to satisfy long term personal financial planning considerations and widen his investment portfolio. Following this transaction, Tony Griffin will continue to retain a beneficial holding of 45,650 ordinary shares which represents 0.042% of the current issued share capital in the Company.

 

The Notification of Dealing Form set out below is provided in accordance with the UK Market Abuse Regulation.

 

Notification of Dealing Form:

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tony Griffin

2.

Reason for the notification

a)

Position/status

Director

b)

Initial notification/amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB0009633180

b)

Nature of the transaction

Sale of Shares

c)

Price(s) and volumes(s)

Price(s)

£ 38.518

Volume(s)

25,000

d)

Aggregated information

-Aggregate volume

- Price

- Total

 

25,000

£38.518

£962,950

 

e)

Date of the transaction

16 April 2021

f)

Place of the transaction

London Stock Exchange

 



 

 

Enquiries:

Dechra Pharmaceuticals PLC


Ian Page, Chief Executive Officer

Office:  +44 (0) 1606 814 730

Paul Sandland, Acting Chief Financial Officer

e-mail: corporate.enquiries@dechra.com

Office:  +44 (0) 1606 814 730

 



TooleyStreet Communications Ltd


Fiona Tooley, Director

e-mail: fiona@tooleystreet.com

Office:  +44 (0) 121 309 0099

Mobile: +44 (0) 7785 703 523

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com 

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKABQBBKDBQD
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.